The Infona portal uses cookies, i.e. strings of text saved by a browser on the user's device. The portal can access those files and use them to remember the user's data, such as their chosen settings (screen view, interface language, etc.), or their login data. By using the Infona portal the user accepts automatic saving and using this information for portal operation purposes. More information on the subject can be found in the Privacy Policy and Terms of Service. By closing this window the user confirms that they have read the information on cookie usage, and they accept the privacy policy and the way cookies are used by the portal. You can change the cookie settings in your browser.
Thalidomide is an effective agent for patients with refractory multiple myeloma (MM) with a response rate of 30–40% at doses of 200–800 mg but with considerable side effects. We questioned whether lower doses of thalidomide in combination with a daily dose of cyclophosphamide might be an effective regimen with fewer side effects. We included 38 patients with relapsed or refractory MM. The median doses...
AbstractWe report a patient who relapsed 12months after undergoing high-dose chemotherapy followed by autologous stem cell transplantation for refractory Hodgkins disease, nodular sclerosis. The patient received sequential single-dose chemotherapy consisting of 140mg/m2 epirubicin, 1.4mg/m2 vincristine, and 50mg/m2 prednisole on day 1, followed by 4000mg/m2 cyclophosphamide on day 15 and 2000mg/m2...
Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.